Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors

• Main Authors: Peter N. Morcos (Author), Jan Schlender (Author), Rolf Burghaus (Author), Jonathan Moss (Author), Adam Lloyd (Author), Barrett H. Childs (Author), Margaret E. Macy (Author), Joel M. Reid (Author), John Chung (Author), Dirk Garmann (Author)
• Formato: Livro
• Publicado em: Wiley, 2023-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Copanlisib is an intravenously administered phosphatidylinositol 3‐kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model‐informed approach was undertaken to support and confirm an empirically selected starting dose of 28 mg/m2 fo...